Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsmedical mutual - ohio Fintepla Prior Auth Policy U…
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy N/A

    Fintepla (fenfluramide) — Recommended Authorization Criteria

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines recommended prior authorization and coverage criteria for Fintepla (fenfluramide) for treatment of seizures in Dravet syndrome and Lennox-Gastaut syndrome in patients aged 2 years and older.

    Policy Summary
    Payermedical mutual - ohio
    PolicyFintepla (fenfluramide) — Recommended Authorization Criteria
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateApr 16, 2026
    Last ReviewApr 16, 2026
    Next Review DateApr 16, 2026
    Key ActionObtain prior authorization and document patient meets initial criteria including age ≥2, diagnosis of DS or LGS, specialist involvement, required echocardiogram, and prior treatment failure as applicable.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2 yrsminimum patient age for coverage
    6 moinitial approval duration
    6 moextended approval / echo interval
    REMSrestricted distribution

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Recommended Authorization Criteria

    inv-01: Initial Therapy

    Covered when ALL of the following are met for initial therapy

    Initial therapy requirements: A. Patient is 2 years of age or older; AND B. Diagnosis of Dravet Syndrome (Severe Myoclonic Epilepsy in Infancy) or Lennox-Gastaut Syndrome (LGS); AND C. Fintepla is prescribed by or in consultation with a neurologist or a provider who specializes in the treatment of Dravet Syndrome or LGS; AND D. Fintepla will not be used concomitantly or within 14 days of the administration of a monoamine oxidase inhibitor (MAOI); AND E. The patient has undergone an echocardiogram prior to initiating therapy with Fintepla; AND F. One of the following: (a) valvular heart disease AND pulmonary arterial hypertension (PAH) were not observed on ECHO; OR (b) valvular heart disease and/or PAH is observed on ECHO and the prescriber attests that the benefits of therapy with Fintepla outweigh the risks; AND G. If diagnosis is Dravet Syndrome: patient has been inadequately controlled on at least ONE antiepileptic drug (AED) or other antiseizure treatment including vagal nerve stimulation or a ketogenic diet; AND H. If diagnosis is LGS: patient has been inadequately controlled on at least ONE AED, with or without vagal nerve stimulation and/or ketogenic diet.

    All subconditions A–H required

    inv-02: Continuation Therapy

    Covered when ALL of the following are met for continuation of therapy

    Continuation therapy requirements: A. Patient has been using Fintepla for at least 6 months; AND B. Patient has had a beneficial response to therapy per the prescriber (e.g., reduced seizure severity, frequency, and/or duration); AND C. Diagnosis of Dravet Syndrome or Lennox-Gastaut Syndrome (LGS); AND D. Fintepla is prescribed by or in consultation with a neurologist or a provider who specializes in the treatment of Dravet Syndrome or LGS; AND E. The patient has undergone a follow-up echocardiogram after at least 6 months of therapy and the ECHO was performed within the past 6 months; AND F. One of the following: (a) valvular heart disease AND pulmonary arterial hypertension (PAH) were not observed on ECHO; OR (b) valvular heart disease and/or PAH is observed on ECHO and the prescriber attests that the benefits of continuing therapy with Fintepla outweigh the risks.

    All subconditions A–F required

    Coverage is provided only for the specific indications and criteria listed in this policy. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. The criteria will be updated as new published data become available.

    Uses that are not described in the Recommended Authorization Criteria are generally not recommended for approval. Requests for other indications or uses will be reviewed on a case‑by‑case basis and are unlikely to be supported without evidence of safety and effectiveness for the requested use.

    Initial Therapy — Detailed Requirements

    inv-11: Initial therapy criteria

    Initial therapy criteria: A. Patient is 2 years of age or older

    Patient age requirement (>=2 years)

    Diagnosis: B. Diagnosis of Dravet Syndrome (Severe Myoclonic Epilepsy in Infancy) OR Lennox-Gastaut Syndrome (LGS)
    Prescriber: C. Fintepla is prescribed by or in consultation with a neurologist or a provider who specializes in the treatment of Dravet Syndrome or LGS
    Safety—MAOI: D. Fintepla will not be used concomitantly or within 14 days of the administration of a monoamine oxidase inhibitor (MAOI)

    Continuation Therapy — Renewal Requirements

    inv-12: Continuation criteria

    Continuation therapy criteria: A. Patient has been using Fintepla for at least 6 months
    Clinical benefit: B. Patient has had a beneficial response to therapy per the prescriber (e.g., reduced seizure severity, frequency, and/or duration)
    Diagnosis: C. Diagnosis of Dravet Syndrome or Lennox-Gastaut Syndrome (LGS)
    Prescriber: D. Fintepla is prescribed by or in consultation with a neurologist or a provider who specializes in the treatment of Dravet Syndrome or LGS

    Provider Requirements and Administrative Actions

    Prior Authorization

    Prior authorization required for Fintepla

    Prior authorization is recommended for pharmacy benefit coverage of Fintepla; approval is recommended only when the patient meets the specified initial therapy criteria (including age, diagnosis, prescriber specialty, MAOI spacing, and echocardiogram requirements).

    Step Therapy

    Step requirement — prior inadequate control required

    Before initiating Fintepla for Dravet syndrome or Lennox-Gastaut syndrome, the patient must have been inadequately controlled on at least one antiepileptic drug or other antiseizure treatment as specified by diagnosis.

    • Dravet: inadequately controlled on ≥1 AED or other antiseizure treatment (includes vagal nerve stimulation or ketogenic diet).
    • LGS: inadequately controlled on ≥1 AED, with or without vagal nerve stimulation and/or ketogenic diet.

    Step Therapy / Prerequisite Treatments

    StepRequirementNotes
    1
    Patient must be inadequately controlled on at least one antiepileptic drug (AED) or other antiseizure treatment prior to initiating Fintepla
    For Dravet syndrome this includes failure of ≥1 AED or other treatment including vagal nerve stimulation (VNS) or a ketogenic diet; for Lennox‑Gastaut syndrome failure of ≥1 AED (with or without VNS and/or ketogenic diet).

    Clinical Background

    Fintepla (fenfluramine) is indicated for the treatment of seizures associated with Dravet syndrome and Lennox‑Gastaut syndrome (LGS) in patients aged 2 years and older. Because fenfluramine has serotonergic activity associated with risks of valvular heart disease and pulmonary arterial hypertension, echocardiogram monitoring is required and use is restricted through the FINTEPLA REMS program. Fintepla is contraindicated within 14 days of MAOI administration and is a Schedule IV controlled substance.

    Key Definitions

    REMS — Risk Evaluation and Mitigation Strategy
    DefinitionRisk Evaluation and Mitigation Strategy (REMS)
    Program requirementFINTEPLA is available only through the FINTEPLA REMS restricted program.
    Safety contextREMS in place because fenfluramine is associated with risk of valvular heart disease and pulmonary arterial hypertension; echocardiogram assessments are required before, during, and after treatment.
    Contraindication related to REMS safetyFINTEPLA is contraindicated within 14 days of monoamine oxidase inhibitor (MAOI) administration due to increased risk of serotonin syndrome.
    Controlled substance statusFINTEPLA contains fenfluramine, a Schedule IV controlled substance.
    Policy Summary
    Payermedical mutual - ohio
    PolicyFintepla (fenfluramide) — Recommended Authorization Criteria
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateApr 16, 2026
    Last ReviewApr 16, 2026
    Next Review DateApr 16, 2026
    Key ActionObtain prior authorization and document patient meets initial criteria including age ≥2, diagnosis of DS or LGS, specialist involvement, required echocardiogram, and prior treatment failure as applicable.
    SourceLink
    On This Page
    Recommended Authorization CriteriaInitial Therapy — Detailed RequirementsContinuation Therapy — Renewal RequirementsProvider Requirements and Administrative ActionsStep Therapy / Prerequisite TreatmentsClinical BackgroundKey Definitions
    Safety—baseline echo: E. The patient has undergone an echocardiogram prior to initiating therapy with Fintepla
    Echocardiogram findings: F. Either: (a) valvular heart disease AND pulmonary arterial hypertension (PAH) were NOT observed on ECHO; OR (b) valvular heart disease and/or PAH is observed on ECHO and the prescriber attests that the benefits of therapy with Fintepla outweigh the risks
    Prior treatment—Dravet: G. If diagnosis is Dravet Syndrome: patient has been inadequately controlled on at least ONE antiepileptic drug (AED) or other antiseizure treatment including vagal nerve stimulation or a ketogenic diet
    Prior treatment—LGS: H. If diagnosis is LGS: patient has been inadequately controlled on at least ONE AED, with or without vagal nerve stimulation and/or ketogenic diet
    Follow-up echocardiogram:
    E. Follow-up echocardiogram performed after at least 6 months of therapy and the ECHO was performed within the past 6 months (FDA recommends ECHO every 6 months)
    Echocardiogram findings: F. Either: (a) valvular heart disease AND pulmonary arterial hypertension (PAH) were NOT observed on ECHO; OR (b) valvular heart disease and/or PAH is observed on ECHO and the prescriber attests that the benefits of continuing therapy with Fintepla outweigh the risks
    Documentation Required

    Provide documentation upon request

    The Company may request additional documentation to support medical necessity; requested documentation must be provided upon request to complete the coverage determination.

    • Examples include patient records, test results, and credentials of the provider ordering or performing the service.
    • Additional documentation supporting medical necessity must be made available upon request.
    Denial Risk

    Potential denial reasons — medical necessity and billing issues

    The Company may deny reimbursement if the drug or service is not medically necessary, is investigational/experimental, is not within the member's benefits, or if there is inappropriate or excessive billing/practice patterns.

    • Denial may follow findings that the service is not medically necessary, investigational, or outside member benefits.
    • A pattern of inappropriate or excessive billing or practice may also result in denial.